title: Hepatitis C virus infection in patients with nonalcoholic chronic liver disease.
abstract: OBJECTIVE
  To determine the prevalence and meaning of antibodies to the hepatitis C virus (HCV) in patients with nonalcoholic chronic liver diseases.
  
  
  METHODS
  Cross-sectional study.
  
  
  METHODS
  The liver unit of a referral-based university hospital.
  
  
  METHODS
  Three hundred and forty-six consecutive patients, including 137 with cryptogenic chronic liver disease, 156 with chronic hepatitis B, 47 with primary biliary cirrhosis, and 8 with persistently abnormal aminotransferase serum levels and normal liver histology. Among patients with cryptogenic liver disease, 41 received blood transfusions before discovery of liver disease and 18 had circulating nonorgan-specific autoantibodies. For comparison, 1495 apparently healthy volunteer blood donors were included in the study. LABORATORY INVESTIGATIONS: The presence of anti-HCV antibodies (anti-HCV) was determined by a recently developed enzyme-linked immunoassay.
  
  
  RESULTS
  In patients with cryptogenic liver disease, the prevalence of anti-HCV was 82% (95% CI, 76% to 89%), being higher (P = 0.02) in patients with histories of blood transfusion than in those with unknown sources of exposure. Antibodies to HCV were not detected in patients with antinuclear antibodies at high titer. Among patients with chronic hepatitis B, anti-HCV were found in 11% (CI, 5% to 18%) of those with hepatitis B virus (HBV)-associated DNA in serum and in 29% (CI, 17% to 43%) of those with undetectable HBV replication (P less than 0.05). The prevalence of anti-HCV in blood donors was 1.2% (CI, 1.1% to 1.3%).
  
  
  CONCLUSIONS
  Our results indicate that HCV infection probably plays an important etiologic role in cryptogenic liver disease and, in some patients, in chronic hepatitis B. Determining whether anti-HCV are present appears to be useful for differentiating viral from autoimmune chronic liver diseases.
authors.affiliation: University of Barcelona, Spain.
authors.forename: J M
authors.initials: JM
authors.lastname: Sánchez-Tapias
authors.forename: J M
authors.initials: JM
authors.lastname: Barrera
authors.forename: J
authors.initials: J
authors.lastname: Costa
authors.forename: M G
authors.initials: MG
authors.lastname: Ercilla
authors.forename: A
authors.initials: A
authors.lastname: Parés
authors.forename: L
authors.initials: L
authors.lastname: Comalrrena
authors.forename: F
authors.initials: F
authors.lastname: Soley
authors.forename: J
authors.initials: J
authors.lastname: Bruix
authors.forename: X
authors.initials: X
authors.lastname: Calvet
authors.forename: M P
authors.initials: MP
authors.lastname: Gil
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000974:Antibodies, Antinuclear / Q000032:analysis; D001782:Blood Donors; D002648:Child; D002908:Chronic Disease; D003430:Cross-Sectional Studies; D005260:Female; D006508:Hepatitis Antibodies / Q000032:analysis; D006509:Hepatitis B / Q000150:complications; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006526:Hepatitis C / Q000150:complications* / Q000453:epidemiology; D006525:Hepatitis, Viral, Human / Q000150:complications*; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000382:microbiology; D008107:Liver Diseases / Q000382:microbiology*; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D016036:Seroepidemiologic Studies; D013030:Spain / Q000453:epidemiology
chemical_list: D000974:Antibodies, Antinuclear; D006508:Hepatitis Antibodies; D006514:Hepatitis B Surface Antigens